skip to Main Content

AIM round-up: Abingdon Health, Karelian Diamond Resource, ValiRx


London’s AIM Index held up well through most of Monday’s session, although the US open deflated sentiment somewhat, leaving the junior market around 10 points lower by 4.30pm at 1221.06.

  • Abingdon Health +46%
  • Karelian Diamond Resources +25%
  • Zoltav Resources -21%
  • Sensyne Health -18%
  • ValiRx -15%

Abingdon Health [LON:ABDX] topped the board, up 46% heading towards the bell. Vatic Health announced a partnership production deal with the company which some investors appear to have latched onto. Given the scale of the gains and the comparative lack of volume, there may be some clarity needed here in the next day or so.

Karelian Diamond Resources [LON:KDR] has also been left sparkling today, up 25%, although the firm with a market cap of just £2m is a comparative minnow and the spread sits in excess of 20% at the time of writing. There’s no news here and trades have been thin on the ground.

Today’s notable mention goes to ValiRx [LON:VAL] who shone last week. Shares were 15% lower approaching the close but that’s still more than 30% up on the week. Last week’s investor presentation reiterated the potential of this company – it might not arrive quickly, if at all, but they’re pursing a virtuous mission.

Zoltav Resources [LON:ZOL] found itself propping up the board by 4.30pm today, some 21% lower off the back of a financing update. Whilst there’s understandably an effort to talk up sentiment here, the underlying theme is one of uncertainty with management exploring alternate options to find an appropriate solution. It’s worth noting that despite the £38m market cap, this is a thinly traded stock and is currently sporting a 25% spread.

Sensyne Health [LON:SENS] slipped 16%, with the stock evidently reacting to lacklustre news coverage in the weekend press. There’s some doubt as to the media interpretation of Friday’s full year results, so taking the glass half full approach this could be seen by some as a buying opportunity for a potential fast-growth company given the stability of the share price in recent weeks.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

The Armchair Trader's 'How to' Guides

In-depth Reports

Detailed reviews of selected companies and investment trusts.

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top